Looking forward to new targeted treatments for chronic spontaneous urticaria

The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease...

http://ift.tt/2jxAR1O